Senators want to know more on why Novo is discontinuing its insulin Levemir

19 Apr 2024
endpts.com
Novo Nordisk decided to discontinue its long-acting insulin Levemir last November, and three Democrats in the Senate want to know why, laying out their questions in a letter to leaders of the company on Tuesday.
Sens. Jeanne Shaheen (D-NH), Elizabeth Warren (D-MA) and Raphael Warnock (D-GA) sought more information on supply constraints and whether Novo would consider producing Levemir until biosimilars are available. They gave Novo until May 1 to respond to the questions.
Senators want to know more on why Novo is discontinuing its insulin Levemir
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.